Within this work, it is aimed to facilitate dual therapy opportunities for the treatment of tuberculosis and prostate cancer separately based on crystal engineering principles. In this regard, a quinolone family member antibiotic namely Sparfloxacin (SPX) is combined with another antibiotic called 4-aminosalicylic acid (4-ASA). Due to the drug-drug combination, it is expected to have superior biological activity since both drugs are stated and offered to be used in the treatment of tuberculosis. In addition to that, Apalutamide (APA) a recent drug in the treatment of castration-sensitive metastatic prostate cancer (CSMPC), is metallo-encapsulated by using zeolitic imidazolate framework-8 (ZIF-8). Owing to pH-sensitive decomposition, the new formulation is expected to combine the benefit of free zinc release and APA release to the targeted cancerous section. Both new compounds are synthesized characterized by various methods such as single crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), Fourier-transform infrared radiation (FTIR), thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and high-performance liquid chromatography (HPLC).